A Randomized, Double-Blind Phase 1 Safety and Pharmacokinetic Study of Q-Griffithsin Douche Administered Rectally to HIV-1 Seronegative Adults (the PREVENT Study)
AIDS Research and Human Retroviruses · 09.11.2026
DOI: 10.1177/08892229261502024 ↗Kurz gefasst
Fachartikel in der Zeitschrift AIDS Research and Human Retroviruses, online erschienen am 09.11.2026. Verfasst von Ken Ho und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Die Arbeit nennt 27 Literaturangaben. Gefördert von: National Institutes of Health (NIH) Department of Allergy & Infectious Disease, Division of AIDS (DAIDS),.
Abstract (Originalsprache)
The availability of oral and long-acting injectable pre-exposure prophylaxis (PrEP) has transformed human immunodeficiency virus (HIV) prevention; however, some individuals may prefer behaviorally congruent, nonsystemic, on-demand rectal PrEP options that avoid chronic systemic exposure. The Q-Griffithsin (Q-GRFT) rectal douche is a novel, user-controlled PrEP candidate, containing a natural (red alga–derived), potent broad-spectrum antiviral lectin for pericoital rectal use. This first-in-human Phase 1 trial evaluated the safety, pharmacokinetics (PKs), pharmacodynamics (PDs), and acceptability of a single Q-GRFT rectal douche dose. Sixteen HIV-negative participants (eight female and eight male) with a history of recent receptive anal intercourse were enrolled in this randomized, double-blind study. Following single-dose administration, blood, rectal fluid, and rectal tissue samples were collected for safety, PK, and PD analyses using an ex vivo rectal explant HIV challenge model. Acceptability was measured using structured questionnaires. The Q-GRFT douche was safe with no Grade 3 or 4 adverse events or significant histological abnormalities. Acceptability was high at 93% of the study product. At 1 h postdose, geometric mean (range) Q-GRFT concentrations were 522.18 ng/mL (52.8–12,482.2) in rectal swab eluate and 6.85 µg (0.80–51.07) in rectal tissue, declining over 24 h. Q-GRFT was not detectable in plasma. Higher individual tissue drug levels correlated with reduced HIV infectivity in both rectal eluate ( p = 0.036) and tissue explant ( p = 0.003). In this first-in-human study, a single administration of Q-GRFT as a rectal douche demonstrated favorable safety, acceptability, and high local drug exposure without systemic absorption, supporting further evaluation as an on-demand, nonsystemic rectal PrEP strategy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA.
- Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.
- Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, Louisville, Kentucky, USA.
- UofL Health-Brown Cancer Center, University of Louisville, Louisville, Kentucky, USA.
- Department of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville, Kentucky, USA.
ORCID-Profile: Ian McGowan, Rhonda M Brand
Förderung
- National Institutes of Health (NIH) Department of Allergy & Infectious Disease, Division of AIDS (DAIDS),
Zitieren
APA
Ho, K., Edick, S., Zyhowski, A., Swistok, A., Meyn, L., Rohan, L., Wang, L., Matoba, N., Lasnik, A., Fuqua, J., Spiegel, H., Hartman, D., Brand, R. E., Cranston, R. D., McGowan, I., Palmer, K., & Brand, R. M. (2026). A Randomized, Double-Blind Phase 1 Safety and Pharmacokinetic Study of Q-Griffithsin Douche Administered Rectally to HIV-1 Seronegative Adults (the PREVENT Study). AIDS Research and Human Retroviruses. https://doi.org/10.1177/08892229261502024
Vancouver
Ho K, Edick S, Zyhowski A, Swistok A, Meyn L, Rohan L, et al. A Randomized, Double-Blind Phase 1 Safety and Pharmacokinetic Study of Q-Griffithsin Douche Administered Rectally to HIV-1 Seronegative Adults (the PREVENT Study). AIDS Research and Human Retroviruses. 2026. doi:10.1177/08892229261502024
BibTeX
@article{Ho2026,
author = {Ho, Ken and Edick, Stacey and Zyhowski, Ashley and Swistok, Amanda and Meyn, Leslie and Rohan, Lisa and Wang, Lin and Matoba, Nobuyuki and Lasnik, Amanda and Fuqua, Joshua and Spiegel, Hans and Hartman, Douglas and Brand, Randall E and Cranston, Ross D and McGowan, Ian and Palmer, Kenneth and Brand, Rhonda M},
title = {A Randomized, Double-Blind Phase 1 Safety and Pharmacokinetic Study of Q-Griffithsin Douche Administered Rectally to HIV-1 Seronegative Adults (the PREVENT Study)},
journal = {AIDS Research and Human Retroviruses},
year = {2026},
doi = {10.1177/08892229261502024}
}
EUVIMED